Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar

Biosimilars are replacing originator compounds due to their similar effectiveness, safety and pharmacokinetics. Our objective was to compare the differences in pharmacokinetics and clinical outcomes between the originator infliximab (Ifx) and the biosimilar CT-P13 in a patient cohort with inflammato...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Martínez-Feito, Ana, Bravo-Gallego, Luz Yadira, Hernández-Breijo, Borja, Diez, Jesús, García-Ramirez, Laura, Jaquotot, Marta, Plasencia-Rodríguez, Chamaida, Nozal, Pilar, Mezcua, Araceli, Martín- Arranz, María Dolores, Pascual-Salcedo, Dora
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7555902/
https://ncbi.nlm.nih.gov/pubmed/33051546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-74235-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky